ID   V_SENDZ                 Reviewed;         384 AA.
AC   P69282;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2005, sequence version 1.
DT   07-OCT-2020, entry version 62.
DE   RecName: Full=Protein V;
GN   Name=P/V/C;
OS   Sendai virus (strain Z) (SeV) (Sendai virus (strain HVJ)).
OC   Viruses; Riboviria; Orthornavirae; Negarnaviricota; Haploviricotina;
OC   Monjiviricetes; Mononegavirales; Paramyxoviridae; Orthoparamyxovirinae;
OC   Respirovirus.
OX   NCBI_TaxID=11198;
OH   NCBI_TaxID=10144; Cavia cutleri (Guinea pig).
OH   NCBI_TaxID=36483; Cricetidae sp. (Hamster).
OH   NCBI_TaxID=10090; Mus musculus (Mouse).
OH   NCBI_TaxID=10116; Rattus norvegicus (Rat).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=6316257; DOI=10.1093/nar/11.21.7317;
RA   Shioda T., Hidaka Y., Kanda T., Shibuta H., Nomoto A., Iwasaki K.;
RT   "Sequence of 3,687 nucleotides from the 3' end of Sendai virus genome RNA
RT   and the predicted amino acid sequences of viral NP, P and C proteins.";
RL   Nucleic Acids Res. 11:7317-7330(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RA   Shibuta H.;
RL   Submitted (FEB-1985) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   RNA EDITING.
RX   PubMed=1655410; DOI=10.1002/j.1460-2075.1991.tb07860.x;
RA   Curran J., Boeck R., Kolakofsky D.;
RT   "The Sendai virus P gene expresses both an essential protein and an
RT   inhibitor of RNA synthesis by shuffling modules via mRNA editing.";
RL   EMBO J. 10:3079-3085(1991).
RN   [4]
RP   ZINC-BINDING DOMAIN, AND MUTAGENESIS OF CYS-337; CYS-341; CYS-353; CYS-355;
RP   CYS-358 AND CYS-365.
RX   PubMed=10933690; DOI=10.1128/jvi.74.17.7834-7841.2000;
RA   Huang C., Kiyotani K., Fujii Y., Fukuhara N., Kato A., Nagai Y.,
RA   Yoshida T., Sakaguchi T.;
RT   "Involvement of the zinc-binding capacity of Sendai virus V protein in
RT   viral pathogenesis.";
RL   J. Virol. 74:7834-7841(2000).
RN   [5]
RP   MUTAGENESIS OF HIS-318; ARG-319; ARG-320; GLU-321; TRP-336; PRO-339;
RP   337-CYS--CYS-341; 353-CYS--CYS-358 AND 362-CYS--CYS-365.
RX   PubMed=12202220; DOI=10.1006/viro.2002.1516;
RA   Fukuhara N., Huang C., Kiyotani K., Yoshida T., Sakaguchi T.;
RT   "Mutational analysis of the Sendai virus V protein: importance of the
RT   conserved residues for Zn binding, virus pathogenesis, and efficient RNA
RT   editing.";
RL   Virology 299:172-181(2002).
RN   [6]
RP   INTERFERON EVASION.
RX   PubMed=15231393; DOI=10.1016/j.virol.2004.04.025;
RA   Komatsu T., Takeuchi K., Yokoo J., Gotoh B.;
RT   "C and V proteins of Sendai virus target signaling pathways leading to IRF-
RT   3 activation for the negative regulation of interferon-beta production.";
RL   Virology 325:137-148(2004).
RN   [7]
RP   SUBCELLULAR LOCATION, FUNCTION, AND INTERACTION WITH HOST IRF3; DDX58 AND
RP   IFIH1.
RX   PubMed=22532687; DOI=10.1128/jvi.06705-11;
RA   Irie T., Kiyotani K., Igarashi T., Yoshida A., Sakaguchi T.;
RT   "Inhibition of interferon regulatory factor 3 activation by paramyxovirus V
RT   protein.";
RL   J. Virol. 86:7136-7145(2012).
CC   -!- FUNCTION: Plays an essential role in the inhibition of host immune
CC       response. Prevents the establishment of cellular antiviral state by
CC       blocking interferon-alpha/beta (IFN-alpha/beta) production and
CC       signaling pathway. Interacts with host IFIH1/MDA5 and DHX58/LGP2 to
CC       inhibit the transduction pathway involved in the activation of IFN-beta
CC       promoter, thus protecting the virus against cell antiviral state.
CC       Interacts also with and inhibits host IRF3.
CC       {ECO:0000269|PubMed:22532687}.
CC   -!- SUBUNIT: Interacts with host IFIH1/MDA5, DDX58 and DHX58/LGP2.
CC       Interacts with host IRF3. {ECO:0000269|PubMed:22532687}.
CC   -!- SUBCELLULAR LOCATION: Host cytoplasm {ECO:0000269|PubMed:22532687}.
CC   -!- DOMAIN: The C-terminal zinc-binding domain is involved in binding to
CC       IFIH1/MDA5 (By similarity). This domain is also involved in viral
CC       pathogenesis. {ECO:0000250}.
CC   -!- RNA EDITING: Modified_positions=318 {ECO:0000269|PubMed:1655410};
CC       Note=Partially edited. RNA editing at this position consists of an
CC       insertion of one or two guanine nucleotides. The sequence displayed
CC       here is the V protein, derived from the +1G edited RNA. The unedited
CC       RNA gives rise to the P protein (AC P04860), the +2G edited RNA gives
CC       rise to the W protein (AC P69283).;
CC   -!- MISCELLANEOUS: The P/V/C gene has two overlapping open reading frames.
CC       One encodes the P/V/W proteins and the other the C/Y proteins.
CC   -!- SIMILARITY: Belongs to the paramyxoviruses V protein family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X00087; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   SMR; P69282; -.
DR   Proteomes; UP000006560; Genome.
DR   GO; GO:0044164; C:host cell cytosol; IDA:CACAO.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:1900226; P:negative regulation of NLRP3 inflammasome complex assembly; IMP:CACAO.
DR   GO; GO:0039503; P:suppression by virus of host innate immune response; IMP:CACAO.
DR   GO; GO:0039548; P:suppression by virus of host IRF3 activity; IDA:CACAO.
DR   GO; GO:0039554; P:suppression by virus of host MDA-5 activity; IEA:UniProtKB-KW.
DR   InterPro; IPR024279; Paramyx_V_Zn-bd.
DR   Pfam; PF13008; zf-Paramyx-P; 1.
PE   1: Evidence at protein level;
KW   Host cytoplasm; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host IRF3 by virus; Inhibition of host MDA5 by virus;
KW   Inhibition of host RLR pathway by virus;
KW   Interferon antiviral system evasion; Metal-binding; Phosphoprotein;
KW   Reference proteome; RNA editing; Viral immunoevasion; Zinc.
FT   CHAIN           1..384
FT                   /note="Protein V"
FT                   /id="PRO_0000142829"
FT   METAL           318
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250"
FT   METAL           337
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250"
FT   METAL           341
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250"
FT   METAL           353
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250"
FT   METAL           355
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250"
FT   METAL           358
FT                   /note="Zinc 2"
FT                   /evidence="ECO:0000250"
FT   METAL           362
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250"
FT   METAL           365
FT                   /note="Zinc 1"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         68
FT                   /note="Phosphoserine; by host"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         125
FT                   /note="Phosphoserine; by host"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         192
FT                   /note="Phosphoserine; by host"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         249
FT                   /note="Phosphoserine; by host"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         257
FT                   /note="Phosphoserine; by host"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         260
FT                   /note="Phosphoserine; by host"
FT                   /evidence="ECO:0000250"
FT   MUTAGEN         318
FT                   /note="H->N: Attenuates viral pathogenicity in mice."
FT                   /evidence="ECO:0000269|PubMed:12202220"
FT   MUTAGEN         319
FT                   /note="R->W: 80% decrease of in vitro zinc binding.
FT                   Attenuates viral pathogenicity in mice."
FT                   /evidence="ECO:0000269|PubMed:12202220"
FT   MUTAGEN         320
FT                   /note="R->G: Attenuates viral pathogenicity in mice."
FT                   /evidence="ECO:0000269|PubMed:12202220"
FT   MUTAGEN         321
FT                   /note="E->K: Attenuates viral pathogenicity in mice."
FT                   /evidence="ECO:0000269|PubMed:12202220"
FT   MUTAGEN         336
FT                   /note="W->G: Attenuates viral pathogenicity in mice."
FT                   /evidence="ECO:0000269|PubMed:12202220"
FT   MUTAGEN         337..341
FT                   /note="CNPVC->SNPVS: 60% decrease of in vitro zinc binding,
FT                   attenuates viral pathogenicity in mice."
FT                   /evidence="ECO:0000269|PubMed:12202220"
FT   MUTAGEN         337
FT                   /note="C->S: 50% decrease of in vitro zinc-binding."
FT                   /evidence="ECO:0000269|PubMed:10933690"
FT   MUTAGEN         339
FT                   /note="P->T: Decreases viral pathogenicity in mice."
FT                   /evidence="ECO:0000269|PubMed:12202220"
FT   MUTAGEN         341
FT                   /note="C->S: 32% decrease of in vitro zinc-binding,
FT                   attenuates viral pathogenicity in mice."
FT                   /evidence="ECO:0000269|PubMed:10933690"
FT   MUTAGEN         353..358
FT                   /note="CVCKTC->RVRKTS: Attenuates viral pathogenicity in
FT                   mice."
FT                   /evidence="ECO:0000269|PubMed:12202220"
FT   MUTAGEN         353
FT                   /note="C->R: 60% decrease of in vitro zinc-binding."
FT                   /evidence="ECO:0000269|PubMed:10933690"
FT   MUTAGEN         355
FT                   /note="C->R: 60% decrease of in vitro zinc-binding."
FT                   /evidence="ECO:0000269|PubMed:10933690"
FT   MUTAGEN         358
FT                   /note="C->S: 55% decrease of in vitro zinc-binding."
FT                   /evidence="ECO:0000269|PubMed:10933690"
FT   MUTAGEN         362..365
FT                   /note="CKLC->SKLR: 60% decrease of in vitro zinc-binding.
FT                   Attenuates viral pathogenicity in mice."
FT                   /evidence="ECO:0000269|PubMed:12202220"
FT   MUTAGEN         365
FT                   /note="C->R: 78% decrease of in vitro zinc-binding.
FT                   Attenuates viral pathogenicity in mice."
FT                   /evidence="ECO:0000269|PubMed:10933690"
SQ   SEQUENCE   384 AA;  41636 MW;  4C768258536BBF36 CRC64;
     MDQDAFILKE DSEVEREAPG GRESLSDVIG FLDAVLSSEP TDIGGDRSWL HNTINTPQGP
     GSAHRAKSEG EGEVSTPSTQ DNRSGEESRV SGRTSKPEAE AHAGNLDKQN IHRAFGGRTG
     TNSVSQDLGD GGDSGILENP PNERGYPRSG IEDENREMAA HPDKRGEDQA EGLPEEVRGS
     TSLPDEGEGG ASNNGRSMEP GSSHSARVTG VLVIPSPELE EAVLRRNKRR PTNSGSKPLT
     PATVPGTRSP PLNRYNSTGS PPGKPPSTQD EHINSGDTPA VRVKDRKPPI GTRSVSDCPA
     NGRSIHPGLE TDSTKKGHRR EHIIYERDGY IVDESWCNPV CSRIRIIPRR ELCVCKTCPK
     VCKLCRDDIQ CMRPDPFCRE IFRS
//
